AZTA reports fiscal Q3 results today against a backdrop that is genuinely uncomfortable: a heavily shorted stock that collapsed after its last earnings release, now trading back near where insiders last sold — a setup that gives the print real teeth.
Short sellers remain a material presence. Nearly 12.8% of the free float is sold short, and while that figure has eased about 9% over the past month, the absolute level keeps the bearish overhang in place. Official FINRA data pegs days-to-cover at close to 10, meaning any sharp positive surprise would take time to unwind. The borrow market itself does not suggest urgency from that camp: availability is generous at over 500% — meaning far more shares remain available to lend than are currently borrowed — and the cost to borrow has dropped 21% over the past week to just 0.39%. Short sellers are not scrambling to cover, but they are not pressing harder either.
Options positioning has turned distinctly defensive ahead of today. The put/call ratio is running at 3.72, well above its 20-day average of 3.20, and has been elevated since mid-July when it jumped from roughly 2.3. That shift in the PCR coincides precisely with a period when the stock was rallying — AZTA is up 17% over the past month and 4% on the week, closing Tuesday at $30.13. Bulls buying into the recovery appear to be hedging simultaneously. The 52-week range on the PCR spans from 0.02 to 7.53, so current levels are not extreme, but the directional shift is notable.
The debate between bulls and bears has been shaped heavily by last quarter's disaster. After the May 6 print, AZTA fell nearly 25% in a single session and nearly 31% over the following five days — a reaction that prompted Needham to cut its target from $44 to $33 while keeping its Buy rating. The most recent consensus target stands at $27.80, a level the stock has now exceeded at $30.13. Bears point to the May quarter's missed estimates, compressed margins, and management's decision to lower long-range targets — signs that the multiomics growth story and North American demand are both softer than previously modelled. Bulls counter that the sample management business has durable structural demand in life sciences automation, and that the stock's price-to-book well below 1 leaves a valuation floor. The EPS momentum factor score of 82 on a 30-day basis suggests near-term estimate revisions have turned more constructive, though the 90-day reading of just 9 and an EPS surprise rank at the bottom of the universe (1st percentile) tell a less forgiving story.
The ownership picture adds one layer of interest. Politan Capital, an activist manager, holds just over 10% of shares. BlackRock added roughly 304,000 shares through June and now controls nearly 15%. That institutional stickiness provides some structural support — but it also means sophisticated holders are watching the same trajectory that sent the stock down 31% in five days three months ago.
The print today is less a question of whether life sciences automation demand is recovering, and more a test of whether management can present a margin and revenue trajectory that justifies a stock trading back above the analysts' consensus target, three months after the Street spent a day repricing it 25% lower.
See the live data behind this article on ORTEX.
Open AZTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Azenta, Inc. heads into its Q2 FY2026 earnings print on May 6 with one of the most aggressive short-interest buildups in the life sciences tools space. Shorts have done most of the work in April. SI as a percentage of…
Azenta heads into its May 5 earnings call carrying the heaviest short interest it has seen in months, a building bearish footprint that arrived just as the stock broke back down from a sharp one-month rally. Short…
